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Activin receptor-like kinase 1 (ALK1) is an endothe-
lial-specific member of the TGF-b/BMP receptor
family that is inactivated in patients with hereditary
hemorrhagic telangiectasia (HHT). How ALK1
signaling regulates angiogenesis remains incom-
pletely understood. Here we show that ALK1 inhibits
angiogenesis by cooperating with the Notch
pathway. Blocking Alk1 signaling during postnatal
development in mice leads to retinal hypervasculari-
zation and the appearance of arteriovenous malfor-
mations (AVMs). Combined blockade of Alk1 and
Notch signaling further exacerbates hypervasculari-
zation, whereas activation of Alk1 by its high-affinity
ligand BMP9 rescues hypersprouting induced by
Notch inhibition. Mechanistically, ALK1-dependent
SMAD signaling synergizes with activated Notch in
stalk cells to induce expression of the Notch targets
HEY1 and HEY2, thereby repressing VEGF signaling,
tip cell formation, and endothelial sprouting. Taken
together, these results uncover a direct link between
ALK1 and Notch signaling during vascular morpho-
genesis that may be relevant to the pathogenesis of
HHT vascular lesions.
INTRODUCTION
Blood vessels form complex branched networks composed of
arteries, capillaries, and veins that supply oxygen and nutrients
to all body tissues. The luminal side of blood vessels is lined
with endothelial cells (ECs), which form an interface between
circulating blood in the lumen and the vessel wall and normally
rest in a quiescent state. Lack of tissue oxygen and nutrient
supply triggers EC activation and sprouting of new vessel
branches from the preexisting vessel network, a process termed
angiogenesis (Geudens and Gerhardt, 2011; Herbert and Stain-
ier, 2011). Angiogenesis is initiated by release of growth factors
from tissue, and requires coordination of a series of cellular
processes including selection of a migrating tip cell at the endDeveloof the sprout, and of other ECs, termed stalk cells, which
proliferate and form tubes (Wacker and Gerhardt, 2011). A key
molecule for the initiation and direction of sprouting is vascular
endothelial growth factor A (VEGF-A, hereafter referred to as
VEGF). When blood vessels are exposed to VEGF, a number of
ECs switch to the tip cell state, whereas others will form the stalk
of the vascular sprout (Gerhardt et al., 2003; Larrive´e et al., 2009).
Tip cells express higher levels of specific molecular markers
compared to stalk cells, including platelet-derived growth factor
B, VEGF receptor (VEGFR)-2, uncoordinated (UNC)5B, Delta-
like (DLL)4, and VEGFR3 (del Toro et al., 2010; Tammela et al.,
2008), which are required for proper patterning of the vascular
network. The Notch pathway, a key regulator of cell fate, has
been shown to be critical to mediate the tip cell/stalk cell switch.
VEGF stimulation of tip cells induces high expression of Dll4,
a transmembraneNotch ligand, whereas stalk cells preferentially
express Jagged1 (Jag1), another Notch ligand (Benedito et al.,
2009). Dll4 expression in tip cells induces Notch activation in
neighboring stalk cells, which in turn regulate expression of
specific target genes including bHLH genes of the Hes/Hey
family, and lead to the upregulation of the decoy receptor
VEGFR1 and downregulation of VEGFR2 and VEGFR3, therefore
limiting the response of these cells to VEGF (Hellstro¨m et al.,
2007; Lobov et al., 2007; Suchting et al., 2007; Tammela et al.,
2008). Newly established lumenized sprouts then remodel into
networks supporting blood flow, become specified as arteries
or veins, and recruit mural cells to stabilize their walls (Potente
et al., 2011). Perfusion of the newly formed networks relieves
tissue demand for oxygen and nutrient supply and arrests vessel
growth. Major questions in vascular biology are how sprouting
ECs coordinate their individual behaviors, and how they build
networks with tissue-specific patterning and functionality.
Abnormally patterned blood vessels are seen in many
diseases, including hereditary hemorrhagic telangiectasia
(HHT) (Dupuis-Girod et al., 2010; Shovlin, 1997). HHT vascular
lesions are characterized by direct arteriovenous connections
without an intervening capillary bed (Shovlin, 1997, 2010). This
results in the formation of telangiectasias and of larger arteriove-
nous malformations (AVMs), which can be encountered in the
lung, brain, and liver. HHT is inherited as an autosomal-dominant
trait and affects about 1 in 5,000 people. The abnormal vascular
structures in HHT type 1 result from inactivating mutations in
ENG, which encodes a TGF-b receptor endoglin, whereas thosepmental Cell 22, 489–500, March 13, 2012 ª2012 Elsevier Inc. 489
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encodes activin receptor-like kinase 1 (ALK1) (Dupuis-Girod
et al., 2010; Johnson et al., 1996). Mutations in SMAD4 are
seen in patients with the combined syndrome of juvenile polypo-
sis and HHT (Gallione et al., 2010). Although it is known that
these three mutations disrupt BMP/TGF-b signaling, the exact
mechanisms by which they cause the HHT phenotype remain
unclear.
ALK1 is an EC-restricted TGF-b type I receptor, which binds to
bone morphogenetic protein (BMP) 9, BMP10, and TGF-b. ALK1
leads to the phosphorylation of SMAD1,5,8, which form active
complexes with the common mediator (co) SMAD SMAD4,
which then accumulate in the nucleus and act as transcription
factors to regulate target gene expression (Orlova et al., 2011).
In addition, ALK1 has also been reported to activate extracel-
lular-regulated kinase (ERK) and Jun N-terminal kinase (JNK)
pathways (David et al., 2007b).
Genetic, pharmacological, and histopathological evidence
points to a critical role for ALK1 signaling in regulating both
developmental and pathologic blood vessel formation (Cunha
and Pietras, 2011). In murine models, Alk1 deficiency results in
early embryonic lethality at E11.5 as a result of defects in the re-
modeling of the primary capillary plexus into a functional network
of arteries, capillaries, and veins (Urness et al., 2000). The ALK1
receptor has long been considered an orphan receptor because
it only weakly binds TGF-b. However, recent studies demon-
strated that ALK1 could bind BMP9 and the closely related
BMP10 (David et al., 2007a; Scharpfenecker et al., 2007).
BMP9 is a circulating factor produced mainly by the liver (Bidart
et al., 2012), and is present in human serum at around 5 ng/ml
(David et al., 2008). BMP9 has been shown to bind with high
affinity to both ALK1 and endoglin, as well as to the BMP type
II receptor (BMPR-II) and activin type II receptor (ActR-II) (David
et al., 2007a; Scharpfenecker et al., 2007). BMP9 inhibits VEGF
and FGF-induced migration and proliferation (David et al.,
2007a; Scharpfenecker et al., 2007) and has therefore been
described as a vascular quiescence factor.
Although recent data have helped understand some of the
cellular processes mediated by ALK1, the mechanisms by which
ALK1 signaling regulates vascular morphogenesis remain
unclear. In zebrafish, the acvrl1mutant violet beauregarde pres-
ents with vascular malformations with blood flow constrained to
a limited number of hyperproliferative cranial vessels, consistent
with a role for ALK1 in promoting vascular quiescence during
development (Corti et al., 2011; Roman et al., 2002). Alk1 also
contributes to homeostasis in mature vessels because global
deletion of the Acvrl1 gene by tamoxifen treatment in postnatal
mice results in AVM formation, severe internal hemorrhaging,
and lethality (Park et al., 2008, 2009). In addition to BMP/
SMAD signaling, dysregulation of other pathways in arteriove-
nous specification, including Notch, has been implicated in the
formation of AVMs. Interestingly, both gain and loss of Notch
signaling can lead to AVM formation (Gale et al., 2004; Krebs
et al., 2004, 2010; Murphy et al., 2009, 2012). AVM formation is
thought to be due at least in part to defective arteriovenous
specification, but the mechanisms by which Notch and ALK1
signaling mediate this process remain largely unknown.
Here we describe a cooperation between the Notch and ALK1
signaling pathways during tip/stalk specification in sprouting490 Developmental Cell 22, 489–500, March 13, 2012 ª2012 Elsevierangiogenesis. We demonstrate that decreased ALK1 signaling
results in EC hypersprouting, and that this effect is caused, at
least in part, by reduced SMAD-induced HEY1 and HEY2
expression. Furthermore, we show that both ALK1 and Notch
signaling can partially compensate for each other in loss-of-
function studies.
RESULTS
Blocking Alk1 Induces Hypervascularization and AVM
Formation
We investigated Alk1 expression and the effects of Alk1 inhibi-
tion on blood vessel development in postnatal mice using the
retinal angiogenesis model. Whole-mount staining of P7 retinas
with an anti-Alk1 antibody showed strong Alk1 expression in
arteries, and lower receptor levels in veins and the capillary
plexus (see Figure S1A available online), as previously reported
in Alk1-lacZ reporter mice (Seki et al., 2003). At the leading
edge of the retina, Alk1 expression was stronger in stalk cells
than in tip cells (Figure S1A). ELISA measurement of circulating
serum Bmp9 levels at different stages of postnatal development
revealed high levels in P6 mice (1.5 ng/ml) that progressively
decreased to stabilize at 8 weeks at 100 pg/ml (Figure S1B).
These data suggested that circulating Bmp9 might activate
Alk1 on lumenized postnatal retinal vessels, including stalk cells.
To examine effects of ALK1 blockade, we generated an
adenovirus encoding the ALK1 extracellular domain (amino
acids 1–118 of human ALK1) fused to the Fc portion of human
immunoglobulin (ALK1Fc), which acts as a ligand trap and
blocks ALK1 signaling in vivo (Niessen et al., 2010). Intraperito-
neal injection of the ALK1Fc virus into neonatal P1 mice induces
complete disappearance of circulating serum Bmp9 (Fig-
ure S1C). ALK1Fc-treated mice developed striking retinal hyper-
vascularization already 3 days after virus injection at P4 (Figures
1A and 1B). At P6, ALK1Fc-treated mice developed a dense
sheet of vessels, with a significant increase in vascularized
area compared to control virus-injected mice (Figures 1C and
1D). At P12, ALK1Fc-treated mice showed defective vessel re-
modeling and arterial patterning defects (Figures 1E–1L). Control
virus-injected retinas had five to six thin, straight arteries radi-
ating out from the optic nerve that were connected to a regular
network of capillaries and veins (Figures 1E–1H). In contrast,
ALK1Fc-treated mice showed fewer and dilated, tortuous
arteries developing in a hyperbranched, dense capillary plexus
(Figures 1I–1L). Remodeling of vessels of the ear, which are
actively growing during the treatment period, was also affected
in ALK1Fc-treated mice, and AVMs had developed in ears of
all treated mice at P12 (Figure 1M).
Adenoviral overexpression of Bmp9 during the first postnatal
week proved difficult, and we failed to obtain consistently
elevated serum levels of Bmp9 beyond the already high endog-
enous expression levels at P6 (Figure S1B). At P12, serum levels
of Adeno-Bmp9-treated mice were consistently higher than
those of control mice and led to significantly decreased neovas-
cularization of the deeper retinal vessel layer (Figures 1N–1P and
S1D). Taken together, these data show that Bmp9 can inhibit
retinal angiogenesis, whereas blocking Bmp9-Alk1 signaling
induces retinal hypervascularization, an effect that is similar to
that observed after inhibition of the Notch signaling pathway.Inc.
Figure 1. Alk1 Signaling Regulates Blood Vessel Morphogenesis
(A–C) IsolectinB4 staining of wild-type P4 (A and B) and P6 (C) retinal vessels after treatment with control (A) or ALK1Fc adenovirus (B and C). Scale bar, 500 mm.
(D) Quantification of vessel density in the area of retina covered by vessels in control adenovirus compared with ALK1Fc adenovirus at P6 (n = 7 mice/group).
(E–L) P12 arterial vascular patterns shown by blue latex dye injected into the left ventricle of control (E–H) and ALK1Fc (I–L) adenovirus-injected pups. (F), (H), (J),
and (L) show the corresponding IsolectinB4 staining of retinal vessels. (G), (H), (K), and (L) are higher magnification pictures of boxes shown in (E), (F), (I), and (J).
Note abnormal artery formation and hypervascularization in ALK1Fc-treated retinas (I–L). A, artery. Scale bars, 200 mm (E, F, I, and J) and 70 mm (G, H, K, and L).
(M) SMA (red) and PECAM-1 (green) staining of P12 ear skin from ALK1Fc adenovirus-treated mice. Note the presence of an AV shunt (arrowhead). Scale bar,
100 mm.
(N and O) IsolectinB4 staining of wild-type P12 retinal vessels after treatment with control (N) or Bmp9 (O) adenovirus. Scale bar, 250 mm.
(P) Quantification of vessel density in control adenovirus compared with Bmp9 adenovirus at P12 (n = 5 mice/group).
All values are mean ± SEM. *p < 0.05; ***p < 0.005; Student’s t test.
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In Vitro and In Vivo
To test how BMP9/ALK1 signaling affects sprouting angiogen-
esis, we cultured human umbilical vein endothelial cells
(HUVECs) in 3D fibrin gels and induced tube formation withDeveloVEGF (Figures 2A and 2B). Recombinant BMP9 protein effi-
ciently suppressed VEGF-induced tube formation (Figures 2A
and 2B), whichmay be due in part to antiproliferative effects (Fig-
ure S2A) (David et al., 2007a, 2008; Scharpfenecker et al., 2007).
Blocking of BMP9/ALK1 signaling using ALK1Fc virus-infectedpmental Cell 22, 489–500, March 13, 2012 ª2012 Elsevier Inc. 491
Figure 2. Effect of Notch and ALK1
Signaling on Endothelial Sprouting In Vitro
and In Vivo
(A) Representative images of HUVECs sprouting in
a fibrin gel in the presence or absence of ALK1 or
Notch agonists and antagonists. Scale bar, 75 mm.
(B) Quantification of tube surface area. Graphs
represent the average of three to five experiments.
(C) Representative images and vascular area
quantification of P5 retinas from wild-type or
Dll4+/ pups that received intraperitoneal injec-
tions of control or Bmp9 blocking antibody. Scale
bar, 120 mm.
(D) Quantification of vascular area at P5 (WT plus
control antibody, n = 9 retinas; WT plus anti-Bmp9
antibody, n = 4 retinas; Dll4+/ plus control anti-
body, n = 9 retinas; Dll4+/ plus anti-Bmp9 anti-
body, n = 9 retinas).
(E) Representative images and quantification of tip
cells of P5 retinas from pups injected with vehicle
control or DAPT that received intraocular injec-
tions of PBS or BMP9. Scale bar, 36 mm.
(F) Quantification tip cells at the vascular front
16 hr after intraocular injection (n = 4 retinas for
control PBS and BMP9; n = 6 retinas for DAPT-
PBS and BMP9).
All values are mean ± SEM. *p < 0.05; **p < 0.01;
***p < 0.005; Student’s t test.
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2B). It is noteworthy that ALK1 inhibition had limited effect on
endothelial sprouting in the absence of VEGF in vitro (Figures
S2B and S2C), suggesting that ALK1 blockade may promote
angiogenesis only in the presence of proangiogenic stimuli.
This was confirmed in vivo by the observation that ALK1 inhibi-
tion did not affect mature established vessels in the skin
(Figure S2D).
To test if ALK1 signaling intersects with the Notch pathway, we
blocked both ALK1 and Notch using ALK1Fc and DAPT.
Combined blockade of both pathways further enhanced tube
formation compared to blockade of each pathway alone (Figures
2A and 2B), indicating that ALK1 and Notch signaling pathways
may interact to inhibit VEGF-induced sprouting. We next exam-
ined the effects of activating one pathway while blocking the492 Developmental Cell 22, 489–500, March 13, 2012 ª2012 Elsevier Inc.other. Jagged-1 (JAG1) peptide-medi-
ated activation of the Notch pathway
was able to suppress ALK1Fc-mediated
hypersprouting, whereas a control-
scrambled peptide that does not activate
Notch did not affect sprouting (Figures 2A
and 2B; data not shown). Likewise, BMP9
was able to reverse the hypersprouting
induced by DAPT (Figures 2A and 2B).
Our in vitro data predicted that
combined Alk1 and Notch inhibition
in vivo should exacerbate hypervasculari-
zation. We tested this hypothesis by in-
jecting an anti-Bmp9 blocking antibody
into Dll4+/ pups, which show increased
tip cell specification and hypersprouting(Suchting et al., 2007). Blockade of Bmp9 induced retinal hyper-
vascularization (Figures 2C and 2D), confirming that the effects
of ALK1Fc (Figures 1A–1D) are likely due to decreased circu-
lating Bmp9 levels. Dll4+/mice showed significant hypervascu-
larization when compared to wild-type littermates (Figures 2C
and 2D). Combined blockade of Alk1 and Notch signaling further
increased hypervascularization when compared to Dll4+/ or
anti-Bmp9-treated wild-type mice (Figures 2C and 2D).
Our in vitro data further predicted that activation of Alk1
signaling should rescue defects induced by Notch inhibition.
To confirm this experimentally, we used DAPT-treated mice,
which received intraocular injections of PBS in one eye and
BMP9 in the other. Twelve hours afterward, DAPT-induced
Notch blockade resulted in increased tip cell formation, deter-
mined by quantification of filopodia-extending cells in the
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ALK1 Modulates Notch Signalingvascular front of the retina (Figures 2E and 2F). BMP9 injection
induced a dramatic decrease in the number of filopodia-extend-
ing cells in control- and DAPT-treated mice (Figures 2E and 2F).
Taken together, the results indicate that BMP9 signaling coun-
teracted hypersprouting induced by Notch inhibition in vitro
and in vivo.
BMP9/ALK1 Signaling Induces Notch Target Gene
Expression
We next examined signaling events induced by ALK1 activation
to determine if ALK1 and Notch converge on common down-
stream pathways. BMP9 stimulation of HUVECs induced rapid
phosphorylation of SMAD1,5,8 as well as phosphorylation of
ERK1,2 (Figure 3A). BMP9 also induced expression of the inhib-
itory SMAD6 2 hr after growth factor addition (Figure 3A).
SMAD1,5,8 and ERK activation was ALK1 dependent, as shown
by siRNA-mediated knockdown of ALK1, which abolished
BMP9-mediated SMAD phosphorylation and decreased phos-
pho-ERK levels (Figure 3B). To examine downstream target
genes induced by Notch and ALK1 activation, we seeded
HUVECs onto plates coated with recombinant sDll4 protein to
activate Notch signaling alone or in the presence of BMP9.
BMP9 but not Dll4 induced expression of ALK1 targets ID1 and
transcription of SMAD6 and SMAD7 (Figure 3C). Dll4 induced
expression of Notch target genes HES1 (data not shown),
HEY1, and HEY2 and upregulated JAG1 levels (Figure 3D). Dll4
did not affect ALK1 mRNA levels (data not shown). Strikingly,
BMP9 treatment alone also induced expression of HES1 (data
not shown), HEY1, HEY2, and JAG1 (Figure 3D). mRNA expres-
sion by BMP9 was induced within 1 hr, and was independent of
protein synthesis (Figure S3A), indicating that BMP9 signaling
directly controls expression of these genes, which is consistent
with a recent study showing direct binding of SMAD1,5 to the
HEY1, HEY2, and JAG1 promoters (Morikawa et al., 2011).
Combined ALK1 and Notch activation synergized to activate
expression of HEY1 and HEY2, with HEY2 levels increasing
more than 1,000-fold after 24 hr treatment (Figure 3D). BMP9
and Dll4 also additively induced expression of the vascular guid-
ance receptor UNC5B, and of VEGFR1, which both counteract
VEGF signaling (Herbert and Stainier, 2011; Koch et al., 2011),
and inhibited expression of the tip cell marker apelin (Figure 3E)
(del Toro et al., 2010).
Analysis of Jag1 and VEGFR1 expression in retinal vessels
following intraocular BMP9 injections showed that both proteins
were upregulated in the angiogenic front of BMP9-treated
compared to control PBS-injected eyes (Figures S3B and
S3C), indicating that the gene expression changes observed
in vitro following BMP9 activation of ALK1 signaling were also
seen in vivo. Taken together, these data show that BMP9-
ALK1 cooperates with the Notch signaling pathway to activate
downstream gene expression, including activation of Notch
targets, inhibitors of VEGF signaling, and suppression of tip
cell markers.
BMP9 Suppression of Angiogenesis Requires SMAD4,
HEY1, and HEY2
We next asked how BMP9-ALK1 downstream signaling could
mechanistically affect Notch signaling. Because BMP9-medi-
ated ALK1 activation leads to SMAD1,5,8 phosphorylation andDeveloERK activation (Figure 2A), we tested if activation of ERK and/
or SMADwas required for BMP9-ALK1-mediated sprouting inhi-
bition and induction of Notch target genes. ERK inhibition using
the pharmacological inhibitor U0126 did not affect BMP9-medi-
ated induction of Notch targets HEY1 and HEY2 (Figures S4A
and S4B). ERK inhibition also did not change BMP9-mediated
inhibition of VEGF-induced HUVEC tube formation in 3D cultures
(Figures S4C and S4D), indicating that this pathway is dispens-
able for ALK1 effects on sprouting and gene expression.
In contrast, siRNA-mediated knockdown of SMAD4 (Fig-
ure S4E), which prevents the formation of the active SMAD
complex, suppressed BMP9-mediated inhibition of HUVEC
sprouting and abolished BMP9-mediated induction of ID1,
HEY1,HEY2, and JAG1 (Figures 4A–4C and 4G). Taken together,
these data show that SMAD signaling is required for BMP9-ALK1
downstream activation of target gene expression and sprouting
inhibition.
Because SMAD signaling was required for induction of Notch
target gene expression, we reasoned that HEY1 and HEY2might
be required for BMP9-mediated inhibition of HUVEC sprouting.
siRNA-mediated knockdown of HEY1 and HEY2 (Figure S4E)
suppressed BMP9-mediated inhibition of tube formation and
effects on downstream gene expression (Figures 4A, 4D, 4E,
and 4G). In contrast, knockdown of RBPJ did not affect BMP9-
mediated suppression of tube formation or induction of HEY1
and HEY2 (Figures 4F, 4G, and S4E), supporting a model
whereby BMP9-ALK1-induced SMAD signaling induces HEY1
and HEY2 independently of canonical Notch activation.
Alk1 Signaling Inhibits Tip Cell Selection
Because both ALK1 and Notch are expressed preferentially in
stalk cells, and inhibit sprouting in vivo and in vitro, we next
asked whether ALK1 signaling could affect endothelial tip/stalk
cell specification. Using mosaic bead-sprouting assays in which
target-specific siRNA-transfected cells were mixed with control
siRNA transfected cells, we found that ALK1 knockdown ECs
were more likely to be present at the tip position of endothelial
sprouts compared to control siRNA (Figures 5A–5C). Further-
more, inhibition of SMAD signaling using SMAD4 siRNA or
knockdown of HEY2 also resulted in increased frequency of
ECs at the tip position (Figures 5C–5E). Taken together, these
results support a model in which ALK1 signaling in stalk cells,
through SMAD1,5,8 and downstream expression of ALK1
targets including HEY transcription factors, prevents tip cell
specification and migration and participates in keeping ECs in
the stalk cell state (Figure 6).
DISCUSSION
The data presented here demonstrate an antiangiogenic role of
ALK1 during early postnatal angiogenesis because inhibition of
this receptor with an ALK1Fc ligand trap resulted in excessive
sprouting angiogenesis. Hypervascularization in ALK1Fc-
treated mice was followed by arteriovenous mispatterning and
AVM formation. Likewise, hypervascularization was found to
precede appearance of HHT vascular lesions in other animal
models of HHT, including Acvrl1 and ENG-inducible mouse
knockouts and zebrafish acvrl1mutants (Corti et al., 2011; Lebrin
et al., 2010; Mahmoud et al., 2010; Park et al., 2009; Romanpmental Cell 22, 489–500, March 13, 2012 ª2012 Elsevier Inc. 493
Figure 3. BMP9 Signals through ALK1 and Regulates Endothelial Gene Expression
(A and B) Western blot analysis of parental HUVECs (A) or control or ALK1 siRNA-transfected HUVECs (B) following stimulation with 10 ng/ml BMP9 for up to 2 hr.
(C–E) qPCR analysis of genes involved in SMAD signaling (C), Notch signaling (D), or tip cell specification (E) induced by ALK1 (BMP9) or Notch (sDll4) signaling in
HUVECs, alone or in combination after 24 hr stimulation. Graphs represent the average of three to five experiments. All values are mean ± SEM. *p < 0.05;
**p < 0.01; ***p < 0.005; Student’s t test.
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than insufficient angiogenesis may be a contributing factor to
HHT lesion formation. Furthermore, ALK1 has been reported to
play a role in transducing hemodynamic forces (Corti et al.,
2011), and altered blood flow in the absence of ALK1 signaling
may participate in the formation of HHT lesions. The effect of
ALK1 blockade on angiogenesis was VEGF dependent,494 Developmental Cell 22, 489–500, March 13, 2012 ª2012 Elseviercautioning against the use of ALK1 inhibitors to treat patholog-
ical tumor angiogenesis (Hu-Lowe et al., 2011; Mitchell et al.,
2010) because it indicates that ALK1 inhibition may lead to
appearance of vascular lesions in regions of active angiogenesis.
The hypervascularization observed in the retina of ALK1Fc-in-
jected pups presented striking similarities to that observed in
mice with genetic deletion of Dll4 or other Notch signalingInc.
Figure 4. ALK1 Regulates Endothelial Sprouting and Gene Expression through SMAD Signaling and HEY
(A–F) Tube formation of siRNA-transfectedHUVECs. (A) Quantification of tube surface area after 3 days of sprouting and 2 days of treatment with or without BMP9
10 ng/ml. (B–F) Representative images of endothelial tubes following siRNA transfection in the absence (top row) or presence (bottom row) of 10 ng/ml BMP9.
Scale bar, 75 mm.
(G) qPCR analysis of genes induced by ALK1 after transfection with control, SMAD4, HEY1, HEY2, or RBPJ siRNA, with or without BMP9 stimulation. Graphs
represent the average of three to five experiments.
All values are mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.005; Student’s t test.
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Figure 5. ALK1 Signaling through SMAD and HEY Prevents Tip Cell Specification
HUVECs transfected with siRNA were labeled with green or red fluorescent dyes, mixed, coated on microcarrier beads, and embedded in fibrin.
(A, B, D, and E) Representative images of sprouts 4 days after siRNA transfection. Scale bar, 65 mm.
(C) Quantification of percentage of target siRNA-transfected cells at the tip position of sprouts. Sprouts on 25–30 beads were quantified per experiment. Graphs
represent the average of three to four experiments. All values are mean ± SEM. *p < 0.05; Student’s t test.
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et al., 2007). This led us to ask whether the Notch and ALK1
pathways interacted to regulate sprouting angiogenesis.
Surprisingly, we observed that SMAD signaling downstream of
BMP9-ALK1 activated transcription of canonical Notch targets
HES1, HEY1, and HEY2, as well as the Notch ligand JAG1,
and synergized with activated Notch in inducing expression of
some of these genes. Furthermore, we showed that SMAD4,
HEY1, and HEY2 are required for BMP9-mediated inhibition of
sprouting and induction of downstream gene expression.
SMAD-mediated induction of Notch targets did not appear to
require canonical Notch signaling because knockdown of
RBPJ did not affect BMP9-mediated sprouting inhibition or
HEY1 and HEY2 induction (Figures 4F and 4G). A recent study
has reported direct binding of SMAD1,5 to the HEY1, HEY2,
JAG1, and UNC5B promoter following EC activation by BMP9
(Morikawa et al., 2011), supporting a model whereby BMP9-
ALK1-induced SMAD signaling induces transcription of select
Notch target genes independently of canonical Notch activation,
and synergizes with activated Notch-RBPJ to fully induce tran-
scription of these targets (Figure 6). Alternatively, previous
studies have shown a direct interaction between activated
SMADS and the Notch intracellular domain, which can stimulate
SMAD binding to DNA and produce a functional synergy
following BMP stimulation of ECs (Dahlqvist et al., 2003; Itoh
et al., 2004; Li et al., 2011). In addition, Notch has been reported
to regulate SMAD1, SMAD2, and SMAD3 expression levels,
thereby modulating TGF-b signaling in ECs (Fu et al., 2009).
The precise molecular mechanisms of interaction between the
SMAD and Notch signaling pathway in ECs following ALK1 acti-
vation remain to be established.
HEY1 andHEY2 are well-established Notch targets in vascular
development (Zhong et al., 2000). Mouse embryos lacking both496 Developmental Cell 22, 489–500, March 13, 2012 ª2012 ElsevierHey1 and Hey2 are embryonic lethal due to severe cardiovas-
cular malformations highly similar to those seen after inactivation
of Notch signaling components (Fischer et al., 2004). HEY1 has
been shown to inhibit VEGFR2 expression downstream of Notch
by direct binding to the VEGFR2 promoter (Taylor et al., 2002),
thereby decreasing VEGF response. In line with these findings,
we found that VEGFR2 levels increased significantly following
HEY2 siRNA-mediated knockdown in a SMAD-independent
manner (data not shown), indicating that decreased VEGFR2
expression by synergistic induction of HEY2 following ALK1
andNotch activationmay contribute to inhibiting VEGF response
in stalk cells. Likewise, BMP9-ALK1 signaling increases VEGFR1
levels, thereby inhibiting VEGF response in stalk cells. Further-
more, BMP9-ALK1 induces JAG1 expression, which contributes
to tip-stalk cell selection by antagonizing Dll4 expression in tip
cells (Benedito et al., 2009). We also observed that UNC5B
was a direct target of ALK1 signaling. UNC5B is expressed in
tip and stalk cells and arterial endothelium, but not in veins (Lar-
rive´e et al., 2007; Lu et al., 2004). UNC5B expression is induced
by VEGF and the homeobox transcription factor HLX in tip cells
(Testori et al., 2011), and appears to be regulated by ALK1 in
stalk cells and arteries. UNC5B counteracts VEGF signaling, as
shown by function-blocking approaches (Koch et al., 2011),
which may contribute to tip-stalk cell selection and/or arterial
integrity and vessel quiescence. Finally, we show that Notch
signaling and ALK signaling cooperate to decrease expression
of the tip cell marker apelin, a secreted polypeptide that induces
stalk cell proliferation via its receptor APLNR (del Toro et al.,
2010; Kasai et al., 2008). Together with the mosaic experiments,
which show that ALK1, SMAD, and HEY-deficient cells more
frequently occupy the tip position of growing vessel sprouts,
these data suggest that ALK1 signaling and Notch signaling
cooperate in stalk cells to inhibit conversion into tip cells.Inc.
Figure 6. WorkingModel for ALK1 Signaling
in ECs
The data suggest that ALK1 signaling, triggered
upon BMP9 binding, activates SMAD1,5,8
signaling, which induces expression of HES1,
HEY1, and HEY2 together with Notch signaling.
ALK1 also induces expression of UNC5B and
VEGFR1, therefore reducing VEGF response and
tip cell specification. This modulation of gene
expression by Alk1 contributes to the stability and
quiescence of the endothelium.
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ALK1 Modulates Notch SignalingOur results show that in addition to activation by Dll4, circu-
lating factors such as BMP9 reinforce Notch signaling by binding
to cognate receptors on stalk cells, together coordinating stalk
to tip cell conversion and angiogenic sprouting. Notch activation
is also positively modulated by inputs from the basement
membrane (Estrach et al., 2011; Stenzel et al., 2011). Sprouting
ECs express integrin receptors and deposit basement
membrane components, including nidogens and laminins for
stalk cells to migrate on (del Toro et al., 2010; Germain et al.,
2010). Laminin-mediated integrin signaling promotes Dll4
expression, thereby reinforcing Notch signaling in stalk cells
and maintaining the stalk cell state (Estrach et al., 2011; Stenzel
et al., 2011). Therefore, Notch signaling in stalk cells is regulated
by inputs from neighboring cells, the basement membrane, and
the circulation.
Our data show that BMP9 through ALK1 functions to limit tip
cell formation. During angiogenic sprouting, an individual tip
cell is estimated to occupy the lead position of a capillary sprout
for only a limited period of time (approximately 4 hr), after which it
is overtaken by another cell (Jakobsson et al., 2010). This ‘‘team
effort’’ of tip and stalk cells to ensure capillary guidance is coor-Developmental Cell 22, 489–50dinated by dynamic interplay between
VEGF and Notch signaling (Geudens
and Gerhardt, 2011; Herbert and Stainier,
2011; Potente et al., 2011). Our data
suggest that ALK1 signaling contributes
to this oscillatory behavior in vivo. BMP9
circulates in the bloodstream during early
postnatal development at levels well
above its reported EC50 in human micro-
vascular endothelium (EC50 = 45 ± 27
pg/ml) (David et al., 2007a). Although
the EC50 of Bmp9 on mouse endothelium
in vivo is not known, we expect that the
Bmp9 levels are sufficient to fully activate
Alk1 in retinal vessels. BMP10 may also
modulate retinal angiogenesis. In addi-
tion to stalk cells and arterial ECs, which
express highest levels of ALK1, tip cells
may also be exposed to extravasated
tissue BMP9, given that immature, devel-
oping vessels are leaky. The high levels of
circulating BMP9 and the robust effects
of ALK1 signaling on stalk cell gene
expression are somewhat at odds withactive stalk to tip cell conversion, suggesting that BMP9
signaling may be decreased in tip cells, perhaps by inhibitory
SMAD6 and SMAD7. In addition, it is possible that BMP antago-
nists may modulate BMP9 activity in the vasculature, even
though BMP9 and BMP10 have not been reported to interact
with BMP antagonists noggin or follistatin (Harrington et al.,
2006; Seemann et al., 2009).
BMPs have been described both as pro- and antiangiogenic
factors depending on the cellular context (David et al., 2008; Su-
zuki et al., 2010). BMP signaling strongly induces expression of
ID1, which promotes endothelial proliferation andmigration (Val-
dimarsdottir et al., 2002). BMP9 also robustly induced ID1
expression but suppressed EC sprouting. ALK1 induced expres-
sion of HEY1 and HEY2, which have been shown to antagonize
ID1 (Itoh et al., 2004), and would therefore suppress its stimula-
tory effects on angiogenesis. The relative levels of induction of
ID1 and HEY transcription factors by different BMPs may poten-
tially contribute to the different activities of BMPs on angiogen-
esis, with antiangiogenic BMPs (BMP9, BMP10) inducing high
levels of HEY and therefore lower levels of ID1 activity. Activation
of ID1 by BMP9 underscores that BMP9-ALK1 signaling also0, March 13, 2012 ª2012 Elsevier Inc. 497
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pendent of Notch signaling.
The results shown here suggest that altered Notch signaling
may contribute to AVMs in patients with HHT type 2 with
ACVRL1mutations. Both Notch loss- and gain-of function muta-
tions cause AVMs (Gale et al., 2004; Krebs et al., 2004, 2010;
Murphy et al., 2009, 2012), but interestingly, the phenotype of
the Acvrl1 knockout mice is more reminiscent of Notch gain-
of-function mutants (Park et al., 2009). In addition, inducible
overexpression of active Notch in transgenic mice has been
shown to induce AVMs, which were resolved following arrest
of transgene expression (Miniati et al., 2010). Furthermore,
human brain AVMs showed increased Notch and Notch ligand
expression, suggesting that once AVMs are established, they
exhibit increased Notch activation. Whether decreased Notch
activation and subsequent hypervascularization following ALK1
blockade contribute to the initial steps of AVM formation in
human HHT lesions remains to be investigated.
EXPERIMENTAL PROCEDURES
Additional methods can be found in Supplemental Experimental Procedures.
Antibodies and Recombinant Proteins
Antibodies against Jag1 (AF599), Bmp9 (AF3209), VEGFR1 (AF471), and Alk1
(AF770) were purchased from R&D Systems (Minneapolis, MN, USA), anti-
CD31 (clone MEC 13.3) was obtained from BD Biosciences, and anti-smooth
muscle actin (SMA) (clone 1A4) was obtained from Sigma-Aldrich. IsolectinB4
and secondary antibodieswere purchased fromMolecular Probes (Invitrogen).
For western blot analysis, antibodies against P-SMAD1,5,8 (9511), SMAD1
(9743), SMAD6 (9519), P-ERK1/2 (4370), and ERK1/2 (4695) were acquired
from Cell Signaling Technology (Beverly, MA, USA). Calcein AM was
purchased from Invitrogen. Recombinant sDll4, BMP9, and VEGF-A were ob-
tained from R&D Systems. DAPT was purchased from Calbiochem. The
17-mer JAG1 peptide (CDDYYYGFGCNKFCRPR), corresponding to amino
acids 187–203 of human JAG1, was previously described (Hellstro¨m et al.,
2007). The scrambled peptide (SC)-JAG1 (RCGPDCFDNYGRYKYCF) was
used as a negative control. Both peptides were synthesized by the Yale
W.M. Keck Foundation. Peptides were dissolved in DMSO (50 mM), aliquoted,
and stored at 20C. Adenoviral constructs are described in Supplemental
Experimental Procedures.
Mice
C57/Bl6 mice (Jackson Laboratories) were maintained in the Animal Research
Center at Yale University. All experiments were approved by the IACUC of Yale
University. The Dll4+/ (CD1) mice have been previously described (Suchting
et al., 2007). To inhibit the Notch pathway, the g-secretase inhibitor DAPT
(Calbiochem), dissolved in sterile sunflower oil, was subcutaneously injected
twice into mice (100 mg/kg) at P4, and the mice were sacrificed 24 hr following
injection. Injection with sunflower oil was used as a negative control. Anti-
Bmp9 (10 mg/kg) was injected intraperitoneally at P1 and P3. Latex blue injec-
tions were performed as previously described (Park et al., 2009).
Intraocular BMP9 Injections
A total of 1 ml of 0.5mg/ml BMP9 dissolved in PBS or 1 ml PBSwas injected into
the eyes of anesthetized P4 mice with a PicoSpritzer III (Intracel, Herts, UK).
Mice were sacrificed 16 hr later, and the retinas were isolated for immunohis-
tochemistry and IsolectinB4 staining.
Cell Culture
HUVECs were obtained from Lonza and cultured in ECGM-2 (Lonza). HEK293
cells were cultured in DMEM (Invitrogen) supplemented with 10% FCS and
penicillin/streptomycin at 37C in 5% CO2. HUVECs were starved overnight
in EBM-2 supplemented with 0.1% FBS prior to stimulation with 10 ng/ml
BMP9 and/or 25 ng/ml VEGF. To assess the effect of BMP9 on gene expres-498 Developmental Cell 22, 489–500, March 13, 2012 ª2012 Elseviersion in the absence of protein synthesis, HUVECs were treated with BMP9 in
the presence of 10 mg/ml cycloheximide (Sigma-Aldrich). For stimulation with
sDll4, 6-well plates were precoated with 10 mg/ml sDll4 before plating cells.
DAPT was dissolved as a 1 mM solution in DMSO and was used at a final
concentration of 2 mM. JAG1 peptide was used at 1 mM.
siRNA Transfection
siRNAs (FlexiTube siRNA) were purchased fromQIAGEN. HUVECswere trans-
fected with 25 pmol siRNA per 6-well with 2.5 ml RNAiMax (Invitrogen) accord-
ing to the instructions of the manufacturer. Cells were used for experiments
48 hr after transfection.
Sprouting Assay
After siRNA transfection, HUVECs (250,000 cells/well in 6-well plates) were
resuspended in 300 ml fibrinogen solution (2.5 mg/ml fibrinogen [Sigma-Al-
drich] in EBM-2 [Lonza] supplemented with 2% FBS and 50 mg/ml aprotinin
[Sigma-Aldrich]), and plated on top of a precoated fibrin layer (400 ml fibrinogen
solution clotted with 1 U thrombin [Sigma-Aldrich] for 20 min at 37C). The
second layer of fibrin was clotted for 1 hr at 37C. C3H10T1/2 cells (250,000
cells/well), in EBM-2 supplemented with 2% FBS and 25 ng/ml VEGF, were
then plated on top of the fibrin layers. Cultures were incubated at 37C, 5%
CO2. Control cultures were grown with VEGF for 2–3 days, VEGF was then
removed, and cultures were grown for another 2–3 days. Growth factors
(VEGF, BMP9), DAPT, JAG1, or ALK1Fc were added after 2–3 days. After
4–6 days, cultures were labeled with 4 mg/ml Calcein AM for 1 hr, and imaged
by fluorescence using a standard FITC filter.
For bead-sprouting assays, HUVECs transfected with siRNA 24 hr prior
were labeled with either PKH26 (red) or PKH67 (green) dyes (Sigma-Aldrich)
according to the instruction of the manufacturer, and coated on cytodex3
microcarrier beads (Sigma-Aldrich) for 24 hr before embedding in a fibrin
gel. Sprouts were imaged 2–4 days later.
Immunohistochemistry on Whole-Mount Retinas
In brief, after sacrificing the animals, the eyes were removed and prefixed in
4% PFA for 20 min at room temperature. The dissected retinas were blocked
overnight at 4C in Tris-HCl 0.1 M-NaCl 150 mM-Blocking Reagent (Pierce)
(TNB)-0.5% Triton X-100. Primary antibodies were then incubated with the
retinas overnight in TNB/0.5% Triton X-100. After washing, the retinas were
incubated with IsolectinB4 in Pblec (1 mM MgCl2, 1 mM CaCl2, 0.1 mM
MnCl2, 1% Triton X-100 in PBS) overnight, incubated with the corresponding
secondary antibody for 2 hr at room temperature, and mounted in fluorescent
mounting medium (DAKO, Carpinteria, CA, USA). Images were acquired on
a Nikon eclipse Ti confocal microscope with the PerkinElmer UltraVIEW
Confocal Imaging System and PerkinElmer Volocity software, and a Leica
M205 FA microscope with the Leica Application Suite (LAS) software.
Statistical Analyses
A two-tailed, unpaired Student’s t test was done to determine statistical signif-
icance by calculating the probability of difference between twomeans (Graph-
Pad Prism 4; GraphPad Software, La Jolla, CA, USA). Differences were
considered statistically significant for p values of 0.05 or less (*p < 0.05,
**p < 0.01, ***p < 0.005). Error estimates are displayed as SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.devcel.2012.02.005.
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